<DOC>
	<DOC>NCT00037219</DOC>
	<brief_summary>Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.</brief_summary>
	<brief_title>The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Positive culture plus at least one clinical sign and symptom consistent with invasive candidiasis preferably within 96 hours of the proposed first dose of study drug Life expectancy: greater than 72 hours Pregnant Females Treatment with other investigational drug(s) within 4 weeks Hypersensitivity to anidulafungin or echinocandin therapy Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Anidulafungin</keyword>
	<keyword>Candidemia</keyword>
	<keyword>Invasive Candidiasis</keyword>
</DOC>